tbuckley/cabot-search huggingface dataset:
Long-Term Effects of Early Pregnancy On the Gene Expression and Properties of Mammary Epithelial Cell Subpopulations in Mice
Authors: F. Meier-Abt, E. Milani, T. Roloff, H. Brinkhaus, S. Duss, D. Meyer, I. Klebba, P. Balwierz, E. van Nimwegen, M. Bentires-Alj
Journal: Annals of Oncology (2013)
Multiple Antibody Formation in Autoimmune Hemolytic Anemia
Authors: Martin C. Rosenthal, Zacharias D. Komninos, William Dameshek
Journal: New England Journal of Medicine (1953)

THE precise role of hemolysins in acquired hemolytic anemia has yet to be determined. In 1908 the discovery of these immune bodies in cases of obscure hemolytic anemia by Chauffard and Troisier1 and by Widal, Abrami and Brulé2 indicated that a new entity had been found, appropriately called "hemolysinic" anemia. For a number of years these concepts appeared to have been forgotten, and it was not until 1937, when Dameshek and Schwartz3 demonstrated hemolysins in 2 of 3 cases of acute hemolytic anemia, that a revival of interest took place. The work of these authors re-emphasized the importance of hemolysins, . . .
O9.09 * EFFICACY AND TOLERABILITY OF LACOSAMIDE IN PATIENTS WITH GLIOMA: A PROSPECTIVE STUDY
Authors: A. Pellerino, L. Bertero, E. Trevisan, M. Magistrello, R. Soffietti, R. Ruda
Journal: Neuro-Oncology (2014)

BACKGROUND: Lacosamide (LCM) has been suggested in some retrospective studies to improve seizure control as an add-on treatment in brain tumor patients. We present here the preliminary results of a prospective study focused on a cohort of patients with gliomas and active epilepsy who received LCM. METHODS: Eligibility criteria were as follows: 1) biopsy-proven grade II or III or IV gliomas according to WHO 2007; 2) persisting seizures (seizure frequency > 1 per month) despite a treatment with 1 or more antiepileptic drugs (AEDs) for at least 3 months and adequate serum concentration; 3) stable steroid dose; 4) available information on tumor response on MRI according to RANO criteria following chemotherapy or radiotherapy; 5) age > 18 years. LCM was given at 50 mg daily for one week with an increase of 50 mg twice daily every week to a target dose of 200-400 mg/day. The endpoints were > 50% decrease of seizure frequency and seizure freedom at 3 and 6 months. RESULTS: Since January 2012 42 patients were enrolled. There were 17 grade II gliomas (5 astrocytomas, 8 oligodendrogliomas, 4 oligoastrocytomas), 13 grade III (4 astrocytomas, 3 oligodendrogliomas, 6 gliomatosis cerebri) and 12 glioblastomas. Ten patients (23.8%) had generalized seizures and 32 (76.2%) partial seizures. Thirty-six patients (85.7%) were on AED monotherapy while 6 (14.3%) on polytherapy. Reasons for introduction of LCM were unacceptable side effects of traditional AEDs in 5 patients (12%) and/or lack of efficacy of previous AEDs associated with either PD in 16 (38%) or without PD in 26 (62%). Median duration of follow up was 6.6 months (range 3-24 months). Among low grade gliomas after 3 months of LCM 5/17 patients (29.4%) had a reduction of >50% of seizure frequency while seizure freedom was obtained in other 3/17 (17.6%); at 6 months a reduction of >50% of seizure frequency was observed in 5 (29.4%) while seizure freedom was obtained in other 2 (11.8%) for overall seizure control of 41.2%. As for high grade gliomas after 3 months 6/25 patients (24%) had a reduction of >50% of seizure frequency while seizure freedom was obtained in other 11/25 (44%); at 6 months a reduction of >50% of seizure frequency was observed in 7/22 (31.8%) and seizure freedom in other 6 (27.3%) for overall seizure control of 59.1% . A resolution of an epileptic status was obtained in 3 patients of whom one receveing LCM alone. Secondary generalized seizures disappeared in 4 patients. However, responding patients were not able to reduce the doses of previous AEDs. Most patients (97.6%) did not report significant toxicities: in 2 cases only LCM was withdrawn due to dizziness and fatigue and resistant epilepsy, respectively. CONCLUSION: Among patients both with high grade and low grade gliomas LCM is well tolerated without interactions with antitumoral treatments. LCM shows significant activity as add-on therapy regardless of tumor response to antineoplastic treatment.
Diastolic Dysfunction in Congestive Heart Failure
Authors: W Grossman
Journal: New England Journal of Medicine (1991)

Jeffrey S. Flier, M.D., Editor Lisa H. Underhill, Assistant Editor So that the coming together depends on the going apart; the systole depends on the diastole; the flow depends on the ebb. — D.H. LawrenceThe terms "heart failure" and "congestive heart failure" are often used interchangeably, emphasizing the importance of congestion in the clinical presentation of patients with heart failure. Congestive manifestations, such as pulmonary or peripheral edema, distended neck veins, dyspnea, and orthopnea, almost invariably indicate elevated right or left ventricular filling pressures. These increased filling pressures may result from primary systolic failure, with passive backup of blood . . .
Abstract 3013: Study of three-dimensional cell culturing influence on DNA methylation profile
Authors: Paula López-Serra, Ignacio Martín-Subero, Manel Esteller
Journal: Cancer Research (2011)

Abstract In this study, we purpose the analysis of the DNA methylation profile of four different human breast cell lines, two non transformed and two tumoral, taking into account the influence of the environment in cell culturing. The extracellular matrix was initially thought to serve as nothing more than a physical support for the cells. However, nowadays is very well known that the extracellular matrix is a key component in cell biology, regulating cell biology and tissue homeostasis. This suggests that there is a bidirectional crosstalk between the cells and the surrounding extracellular matrix. Cell culturing is a commonly used technique in all areas of biology research. Usually, adherent cells are spreading in two-dimensional plates where they growth attached to the plastic surface in two directions. Mammary epithelial cells that are cultured on this conventional way fail to form acinar-like structures and loss tissue specific protein expression. Many of the microenvironment influences can be restored in cell culturing models by using three-dimensional cultures in extracellular matrix gels. 3D culturing of epithelial cells can help to reconstruct the acinar morphology seen in vivo and restore some mammary-specific function, like milk proteins production. DNA methylation plays a significant role in the epigenetic regulation of chromatin structure and gene expression. In this work, we tried to analyze the DNA methylation profile of four different human breast cell lines growth in 2 and 3 dimensions to assess the influence of DNA methylation in the two models. HMEC (finite lifespan human mammary epithelial cell line), MCF10A (spontaneously immortalized, but not transform, human breast epithelial cell line), MCF7 (human breast adenocarcinoma cell line, metastasic) and MDA-MB-231 (human breast adenocarcinoma cell line, metastasic) were growth in plates with and without MatrigelTM basement Membrane Matrix Growth Factor Reduced (BD). 3D culturing was done by spreading the cells in the matrix surface and allowing them to form the characteristic acini of the mammary gland. Morphological differences are evident between the 2 and 3D culture models, being much more accurate the 3D model from a phenotypic point of view. DNA mehtylation status was done by illumina's Infinium Microarrays, comparing the methylation profile of each cell line growth in 2 and 3D. We determined in this way which genes are differentially methylated in 2 and 3 dimensions. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3013. doi:10.1158/1538-7445.AM2011-3013
Case 16-1990
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Edward R. Wolpow, Edward P. Richardson, Eugene J. Mark
Journal: New England Journal of Medicine (1990)

Presentation of CaseA 57-year-old woman was admitted to the hospital because of headache, somnolence, increasing right hemiparesis, and a ring-enhancing lesion in the left thalamus.The patient was in a stable state of health until four days earlier, when she awoke with a left-sided headache, bilateral periorbital pain, and fatigue and returned to sleep for most of that day. Three days before admission she began to fall toward the right while walking, and her family noticed subtle problems with her speech; she remained somnolent. On the following day the right arm was weak. The patient was admitted to a . . .
Quality versus queasy: Trends in the use of antiemetics.
Authors: Jayan Nair, Brendan F. Curley, Richard Fong, Jimmy Hwang, Michael Thomas Byrne
Journal: Journal of Clinical Oncology (2015)

203 Background: The American Society of Clinical Oncology (ASCO) launched the Quality Oncology Practice Initiative (QOPI) program in 2010, to promote quality cancer care. Subsequently, ASCO has influenced the use of the neurokinin 1 (NK1) receptor antagonists aprepitant/fosaprepitant through peer-reviewed publications and the Choosing Wisely Campaign. These agents increase cost and, via CYP3A4 inhibition, may lead to drug interactions. Here we report our survey results that explored prescribing patterns of these agents among QOPI-certified and non-certified oncologists. Methods: An anonymous online survey was distributed to oncologists in four states. Respondents were asked 12 questions about the use of aprepitant/fosaprepitant in their clinical practice. Responses were analyzed in aggregate using likelihood ratio Chi-square tests. P-values of &lt; 0.05 are significant. Descriptive statistics describe differences between groups. Results: We analyzed 157 responses and excluded 10 respondents that did not identify themselves as medical oncologists. 62.1% of the practitioners practice in a QOPI-certified practice (90/145). Compared with non-QOPI practitioners, QOPI physicians are significantly more likely to use NK1 antagonists with intermediate/low emetogenicity regimens like weekly cisplatin for head &amp; neck cancer (83.3 vs. 28.0%, p: &lt; 0.001), cervical &amp; bladder cancer (85.2 vs. 34.0%, p: &lt; 0.001), and with CHOP ± rituximab for lymphoma (82.4 vs. 18.0%, p: &lt; 0.001). Significantly, the majority of QOPI-certified physicians report using these agents for the sole purpose of earning/maintaining QOPI certification (81.4-85.4%). QOPI-certified physicians are also significantly more likely to appropriately prescribe NK1 antagonists with doxorubicin ≥ 60 mg/m 2 (86.4 vs. 51.9%, p: &lt; 0.001), cisplatin ≥ 50 mg/m 2 (96.3 vs. 76.9%, p: &lt; 0.001) and dacarbazine (84.6 vs. 55.8%, p: &lt; 0.001). Conclusions: Although QOPI-certified physicians are significantly more likely to use NK1 antagonists than non-QOPI physicians, our findings indicate that their motivation is to satisfy QOPI guidelines instead of perceived necessity. A prospective study may be beneficial to further define the role of NK1 antagonists with intermediate/low emetogenicity regimens.
The tyrosine kinase receptor Met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma
Authors: D Capello, G Gaidano, M Gallicchio, A Gloghini, E Medico, D Vivenza, D Buonaiuto, L Fassone, GC Avanzi, G Saglio, M Prat, A Carbone
Journal: Leukemia (2000)
Use of artificial tissue to practice endoscopic submucosal dissection
Authors: H.-Y. Wang, S.-C. Shih, C.-Y. Hung, T.-Y. Shieh, Y.-B. Chen, M.-J. Chen
Journal: Endoscopy (2013)

Endoscopic submucosal dissection (ESD) is a complex interventional procedure involving several skills and diverse instruments. A consensus from European experts suggested that training for ESD should be performed in a stepwise approach, from knowledge sharing to hands-on ESD experience in an isolated pig stomach model or in live pigs [1]. We have previously developed realistic models to provide clinical practice for ESD in ex vivo or live pig models [2] [3]. In this study, we aimed to evaluate the feasibility of using an artificial tissue in ESD training. To our knowledge, this novel approach has not been previously reported.
Fake meat scandals add to Chinese food fears
Authors: C. Dai, M. Jiang
Journal: BMJ (2013)

First there were 20 000 dead pigs floating down the Huangpu river,1 2 a main source of water for Shanghai city. That was followed by thousands of dead ducks in the Nanhe river in the southwest province of Sichuan. Dead pigs and ducks had been used in the production of fake meat. …
AB0390 Serum RANKL Activity is Suppressed by TNF Alpha Inhibition but not with MTX Alone
Authors: J. Nedovic, B. Stamenkovic, S. Stojanovic
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Bone is, together with cartilage a central target of rheumatoid arthritis (RA). Chronic synovitis attacks the juxtaarticular bone, where it causes bone erosions. Formation of bone erosions is a consequence of osteoclasts activity. Osteoclasts are generated from mononuclear precursor cells mediated by the receptor activator of NF-kappaB ligand (RANKL). Tumor necrosis factor alpha (TNF) is considered as a most important proinflammatory cytokine and also, a mediator of structural damage in RA. TNF is an important inducer of osteoclast formation by increasing production of RANKL and is thus a key molecular link between inflammation and bone damage. <h3>Objectives</h3> The aim of our study was to investigate whether the serum concentration of RANKL is influenced by therapy with and without TNF inhibitors or by disease activity itself. <h3>Methods</h3> 45 RA patients (86,7% female, mean age 55,09±11,61 years) who fulfilled 1987. ACR criteria for RA and 20 age-matched controls with osteoarthritis were enrolled in the study. Group of RA patients consisted from 25 patients treated with Methotrexate (MTX group), mean disease duration 6,83±4,78 years and from 20 patients treated with Methotrexte and Etanercept (TNF group), mean disease duration 9,8±5,59 years. The serum levels of RANKL was determined by commercially available ELISA kit, values expressed in pg/ml. Disease activity was measured by Erythrocyte Sedimentation Rate (ESR) in mm, concentration of hsCRP in mg/L and wit composite index DAS28. <h3>Results</h3> The mean values of serum concentrations of RANKL in MTX group, TNF group and in control group were: 246,81±226,06; 134,53±86,85 and 122,85±138,89 respectively. Patients in MTX group had statistically significantly higher values of RANKL compared with patients in TNF group and in control group, p&lt;0,05. There were no significant differences between patients from TNF and control group. DAS28 was significantly higher in MTX group (6,08±1,16) compared to TNF group (3,18±1,04), p&lt;0,001. Values of ESR were also higher in MTX group as compared to TNF group and control group: 41,44±18,68; 22,45±11,88 and 13,15±6,89 respectively, p&lt;0,01 as well as the values of hsCRP: 9,91±14,45; 1,99±1,79 and 1,52±1,33, p&lt;0,001. There were no significant differences between TNF and control group neither in level of ESR nor in hsCRP. <h3>Conclusions</h3> In our study we determined that concomitant treatment with TNF blocker and MTX significantly reduce the concentration and thus activity of RANKL as compared to treatment with MTX alone. Thus, it is possible that the bone protective effect of anti TNF agents is at least partly, mediated through the RANKL. We also find that concentration of RANKL was in correlation with disease activity as expected. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6016
DIFFERENTIAL IMPACT OF HIGH PLATELET REACTIVITY ON CLOPIDOGREL IN WOMEN AND MEN FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) WITH DES
Authors: Jennifer Yu, Roxana Mehran, Usman Baber, Sze-Yuan Ooi, Bernhard Witzenbichler, Giora Weisz, Michael Rinaldi, FJ Neumann, David Metzger, Timothy Henry, David Cox, Peter Duffy, Ernest Mazzaferri, Bruce Brodie, Thomas Stuckey, Akiko Maehara, Ke Xu, Ajay Kirtane, Gregg Stone
Journal: Journal of the American College of Cardiology (2015)
FRI0467 Is fatigue discriminant in early spondyloarthritis (SPA)? the desir early spa cohort
Authors: L. Gossec, S. Paternotte, M. A. D’Agostino, M. Dougados, B. Fautrel
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Patient-perceived symptoms such as pain, stiffness, and fatigue are important in spondyloarthritis (SpA); in established SpA, fatigue is frequent. The causes of fatigue in inflammatory rheumatisms such as SpA or rheumatoid arthritis are unclear; fatigue is diversely reported as being related either to patient characteristics, e.g., demographic, psychological and social factors, or to disease characteristics, e.g. disease activity. <h3>Objectives</h3> To evaluate the magnitude of fatigue in early SpA (and in the different subtypes of SpA) and to assess if fatigue appears more strongly associated with patient- or with disease-related characteristics. <h3>Methods</h3> Patients: Those in DESIR, a national observational cohort of patients with recent (&lt;3 yrs duration) inflammatory back pain suggestive of SpA according to the investigator. Magnitude of fatigue was assessed by a visual analog scale 0-10 assessment at inclusion and at one year, in the whole population, and according to satisfaction of the ASAS classification criteria, and also to disease subtype (axial versus peripheral versus undifferentiated). Factors associated with high fatigue (&gt;5/10) at 12 months were assessed by multivariate logistic regression, only for patients satisfying the ASAS criteria. The factors tested for association were patient related characteristics including demographic variables (age, gender, symptom duration) and socio-economic status; disease-related characteristics at 12 months including activity (ASDAS, BASFI, BAS-G, HAQ-AS) and other characteristics (HLA B27, disease subtype, and extra-articular involvement). <h3>Results</h3> Of the 708 DESIR patients (mean±SD age 34±9; 327: 46% males), 486 fulfilled the ASAS criteria for SpA (mean age 33±9; 244: 50%, males). Magnitude of fatigue was high at baseline (mean fatigue, 5.7±2.3) and was similar in patients fulfilling the ASAS criteria or not (respectively, mean fatigue 5.5±2.4 and 6.0±2.2). Fatigue levels according to the disease subtype were also similar. Fatigue decreased over the first year of follow-up (mean fatigue at one year, 4.9±2.6). High fatigue at 12 months was well explained (AUC of the model, 0.86) by the following elements: ASDAS-CRP (odds ratio, 2.5 [1.8-3.3], p&lt;0.0001), BASFI (OR, 1.06 [1.04-1.09], p&lt;0.0001), BAS-G (OR, 1.12 [1.02-1.24], p=0.021) and HAQ-AS (OR, 0.41 [0.18-0.95], p=0.037). <h3>Conclusions</h3> Fatigue levels were high in patients with symptoms compatible with early SpA but fatigue did not discriminate between patients with or without the ASAS criteria for SpA. Fatigue levels decreased over the first year of follow-up in DESIR, possibly due to the treatments given. High fatigue at one year was closely related to disease activity rather than to patient-related variables, indicating fatigue seems more strongly related to the disease process in SpA than in rheumatoid arthritis. <h3>Disclosure of Interest</h3> None Declared
Abstract P2-07-07: Ehm2 Influences the Aggressiveness of Breast Cancer Cells through Regulation of MMP-9 Expression, and Aberrant Expression of Ehm2 Correlates with Disease Progression in Breast Cancer
Authors: H Yu, L Ye, Y Zhang, RE Mansel, WG. Jiang
Journal: Cancer Research (2010)

Abstract Background. Ehm2 is a member of NF2/ERM/4.1 superfamily and has been indicated in cell membrane/cytoskeletal interaction and cellular motility. In the present study, we investigated the expression pattern of Ehm2 in breast cancer and the impact of Ehm2 on the biological behavior of breast cancer cells. Methods. A cohort of breast cancer specimens (normal, n=33; cancer, n=127) was tested for Ehm2 expression, using both quantitative real time PCR and immunohistochemical staining. A hammerhead ribozyme transgene was employed to knockdown Ehm2 expression in breast cancer cells. The effect on growth, cell matrix adhesion, motility and invasion by Ehm2 knockdown was then examined using in vitro assays. Results. Immunohistochemical staining and quantitative real time PCR revealed an increased expression of Ehm2 in breast cancer. High levels of Ehm2 transcripts correlated with disease progression, metastasis and poor prognosis. Disease free survival of the patients with lower level of Ehm2 was 135.8 (125.1-146.5, 95%CI) months, significantly longer compared with 102.5 (78.7-126.4, 95%CI) months of patients with higher level of Ehm2 expression, P=0.039. Knockdown of Ehm2 had inhibitory effects on both in vitro growth and invasion of breast cancer cells. Flow cytometric analysis showed that knockdown of Ehm2 resulted in an increase (&amp;gt;10%) of apoptotic cells overthe control cells. Furthermore, it was shown that knockdown of Ehm2 significantly decreased the protein and mRNA expression of matrix metalloprotease MMP9. Zymograhpy revealed a reduced activity of MMP9 in breast cancer cells after knockdown of Ehm2. In conclusion, Ehm2 is able to promote invasion of cancer cells via regulating MMP9, and can also protect them from apoptosis. This may have important implication in the correlation between increased Ehm2 expression and poor prognosis and metastasis in breast cancer. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-07-07.